Trial
NCT00004935
Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Breast Cancer
Intervention
Herceptin™ (Her)
Why stopped
Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-18